Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

por Soini, Erkki, Asseburg, Christian, Taiha, Maarit, Puolakka, Kari, Purcaru, Oana, Luosujärvi, Riitta
Publicado 2017

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised control...

por Väänänen, Tuija, Vuolteenaho, Katriina, Kautiainen, Hannu, Nieminen, Riina, Möttönen, Timo, Hannonen, Pekka, Korpela, Markku, Kauppi, Markku J., Laiho, Kari, Kaipiainen-Seppänen, Oili, Luosujärvi, Riitta, Uusitalo, Tea, Uutela, Toini, Leirisalo-Repo, Marjatta, Moilanen, Eeva
Publicado 2017